Related Experiment Video
Updated: Jan 22, 2026
Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation
1Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, 97080 Würzburg, Germany. harald.wajant@mail.uni-wuerzburg.de.
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptors TRAILR1/death receptor 4 (DR4) and TRAILR2/DR5 trigger cell death in many cancer cells but rarely exert cytotoxic activity on non-transformed cells. Against this background, a variety of recombinant TRAIL variants and anti-TRAIL death receptor antibodies have been developed and tested in preclinical and clinical studies. Despite promising results from mice tumor models, TRAIL death receptor targeting has failed so far in clinical studies to show satisfying anti-tumor efficacy. These disappointing results can largely be explained by two issues: First, tumor cells can acquire TRAIL resistance by several mechanisms defining a need for combination therapies with appropriate sensitizing drugs. Second, there is now growing preclinical evidence that soluble TRAIL variants but also bivalent anti-TRAIL death receptor antibodies typically require oligomerization or plasma membrane anchoring to achieve maximum activity. This review discusses the need for oligomerization and plasma membrane attachment for the activity of TRAIL death receptor agonists in view of what is known about the molecular mechanisms of how TRAIL death receptors trigger intracellular cell death signaling. In particular, it will be highlighted which consequences this has for the development of next generation TRAIL death receptor agonists and their potential clinical application.
Insights
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) agonists show promise but require specific activation. Oligomerization and membrane anchoring are crucial for TRAIL death receptor agonists to effectively trigger cancer cell death.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its death receptors (TRAILR1/DR4, TRAILR2/DR5) induce cancer cell death but have limited efficacy in clinical trials.
- Mechanisms of TRAIL resistance in tumors and the requirement for oligomerization/membrane anchoring of TRAIL agonists hinder clinical success.
Purpose of the Study:
- To review the molecular mechanisms underlying TRAIL death receptor signaling.
- To discuss the necessity of oligomerization and plasma membrane attachment for TRAIL death receptor agonist activity.
- To highlight implications for developing next-generation TRAIL-based cancer therapies.
Main Methods:
- Review of existing preclinical and clinical studies on TRAIL agonists.
- Analysis of molecular mechanisms of TRAIL death receptor-mediated apoptosis.
- Discussion of structure-activity relationships for TRAIL agonists.
Main Results:
- TRAIL agonists require specific structural configurations, such as oligomerization and membrane anchoring, for maximal cytotoxic activity.
- Tumor cells can develop resistance to TRAIL, necessitating combination therapies.
- Understanding these requirements is key to overcoming clinical limitations.
Conclusions:
- Next-generation TRAIL death receptor agonists should be designed to promote oligomerization and/or membrane attachment.
- Targeting TRAIL death receptors effectively requires overcoming resistance mechanisms and optimizing agonist structure for enhanced activity.
- Further development is needed for successful clinical application of TRAIL-based cancer treatments.
Related Concept Videos
01:24Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:25Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...